I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $412.12M |
||||
Company | Location | Date | Amt. (M) | Details |
Agilix Corp. | New Haven, | 12/18 | $20.8 | Company raised $20.8M in a Series B financing; investors were Burrill & Co., Hambrecht & Quist Capital Management Inc., Stephens Group Inc., Wheatley MedTech Partners, BioVeda Capital Pte. Ltd. and ATP Capital |
| ||||
Altus Inc. | Cambridge, | 12/27 | $15 | Altus raised $15M in the second closing of its Series B financing; investors included U.S. Venture Partners and Nomura International plc, CMEA Ventures, China Development Industrial Bank, Hotung International Company Ltd. and the Palladin Group |
| ||||
Amnis Corp. | Seattle | 12/3 | $8.75 | Amnis completed a second round of financing, raising about $8.75M; investors were Orbimed Advisors LLC, Emerging Technology Partners, TVM Techno Venture Management, Sunshine Capital, Hillman Ventures, Integra Ventures, WRF Capital and Stratos Product Development LLC |
| ||||
Astex | Cambridge, | 12/17 | $8.1 | Astex received $8.1M from its investors, Abingworth, Advent International, Alta Partners, GIMV and Oxford Bioscience Partners |
| ||||
Avalon | Gaithersburg, | 12/17 | $70 | Avalon raised $70M in a Series B round of private equity financing; CDP Sofinov served as lead investor; other investors were EuclidSR Partners, AIG Global Investment Group, Hambrecht & Quist Capital Management, MDS Capital, RBC Capital Partners, GeneChem Inc., OrbiMed Advisors LLC, KBL Healthcare Ventures, Oxford Bioscience Partners, GIMV NV, Forward Ventures and Emerging Technology Partners LLC; Array Capital LLC acted as lead placement agent |
| ||||
A-Viral A/S | Oslo, Norway | 12/19** | NOK15 | A-Viral raised US$1.7M in a directed offering |
| ||||
Calyx | Hayward, | 12/5 | $30 | Calyx raised $30M in its fourth financing round led by BA Venture Partners and Walden International; other investors were A.M. Pappas & Associates, U.S. Venture Partners, ABS Ventures and Morgenthaler |
| ||||
Cytochroma | Kingston, | 12/18 | $2.3 | Cytrochroma added US$2.3M in the second tranche of its Series B financing, bringing the total raised to US$9.9M; investors were T2C2 Bio/2000 LP, CDP Sofinov, The Business Development Bank, Novo A/S, GenChem Technologies Venture Fund LP, Canadian Medical Discoveries Fund, Working Ventures Canadian Fund Inc. and VentureLink Capital Corp. |
| ||||
ExonHit | Paris | 12/3 | EUR30 | Company completed its third round of financing, raising US$26.7M; investors included Dresdner Kleinwort Capital, Danske Bank, LCF E. de Rothschild, Sudinnova, BNP-Paribas' Banexi Venture III, CDC Innovation, AGF Private Equity, Oxford Bioscience Partners and Sofinnova Partners |
| ||||
Genome | Grenoble, | 12/10 | EUR12.4 (US | Genome Express raised US$11.02M in a second-round financing |
| ||||
Guava | Burlingame, | 12/20 | $6 | Guava raised $6M in a Series D round of funding |
| ||||
Gyros AB | Stockholm, | 12/17 | $30 | Gyros raised about $30M during a second-round financing led by 3i; other investors were the Swedish Industrial Development Fund, InnovationsKapital, H&B Capital, Investor AB, the National Pension Insurance Fund, Karolinska Investment Fund, HealthCap and the Swedish Union of Clerical and Technical Employees in Industry |
| ||||
Infigen Inc. | Deforest, | 12/19 | ND | Infigen completed a private placement of preferred stock to individuals and institutions; investors included ING Barings Capital and private equity firm Ardshiel Inc.; the company did not disclose the amount raised |
| ||||
Micromet | Martinsried, | 12/26** | EUR6 | Micromet raised US$5.3M in a second closing of its fourth private placement round; investors were HBM BioVentures and the Medical Biohealth-Trends fund |
| ||||
Mindset Bio- | Jerusalem | 12/20 | $15 | Mindset raised $15M, which it will receive in two tranches; investors were MPM Capital LP and Clal Biotechnology Industries Ltd., among others |
| ||||
MitoKor | San Diego | 12/21 | $25 | MitoKor raised $25M; RBC Capital Markets acted as placement agent; investors included Federated Kaufmann Fund, Orbitex Health and Biotechnology Funds, Palladin Group, China Development Industrial Bank, First Bio Venture Capital, Emerging Growth Management Funds, DRW Venture Partners, Alta Partners, Forward Ventures, Domain Associates/3i Bioscience Investment Trust, MDS Capital Corp. and S.R. One |
| ||||
Myogen | Denver | 12/31 | $14 | Myogen raised another $14M in its Series D financing, bringing the total raised to $66.4M; investors included the Perseus-Soros BioPharmaceutical Fund LP, China Development Industrial Bank, Hunt Ventures, Silicon Valley Bank and affiliates of Tenex Medical Investors |
| ||||
Novocell | Irvine, Calif. | 12/19 | $5 | Novocell raised $5M in a Series C financing led by SurModics Inc.; other investors were Asset Management, Alloy Ventures, BD Ventures LLC, Pacific Horizon Ventures and The Vertical Group |
| ||||
Performance | Kingston, | 12/21 | $2.7 | Performance Plants completed $2.7M in additional financing; investors included Venture-Link Fund, Dynex Capital Ltd. Partnership, Saskatchewan Opportunities and Queen's University's Parteq Innovations |
| ||||
Pharmacore | Uppsala, | 12/26** | SEK45 | Pharmacore raised US$4.5M in first-round funding from Swedish investors Innovations-Kapital, Swedestart and A+ Science Invest |
| ||||
Pharmion | Boulder, | 12/3 | $65 | Pharmion raised $65M in a private financing; Nomura International's Private Equity Group led the round; other investors were New Enterprise Associates, Bay City Capital Fund III, Proquest Investments, NeoMed Management, Invemed Fund, HealthCap, Merlin BioMed Private Equity Fund and Montagu Newhall, as well as Domain Associates LLC, Versant Ventures, Aberdare Ventures, Abingworth Management and members of the Pharmion management team; Bay City Capital BD LLC acted as an adviser |
| ||||
Phylogix | Scarborough, | 12/7 | $2.95 | Phylogix completed a $2.95M Series A round of financing led by Biotechnology Value Fund LP, and including Small Enterprise Growth Fund |
| ||||
Synaptica | Oxford, UK | 12/17 | $5.1 | Company completed funding of $5.1M from existing investors |
| ||||
Syrrx Inc. | San Diego | 12/26 | $18.5 | Syrrx raised $18.5M in a financing led by HBM Partners and including new and existing investors |
| ||||
Trellis Bio- | San Francisco | 12/3 | ND | Trellis completed a Series A financing from Forward Ventures and Easton Hunt Capital |
| ||||
Xantos Bio- | Martinsried, | 12/26** | EUR21 | Xantos raised US$18.7M in its second round of financing; investors were GIMV, Oxford Bioscience Partners, The Global Life Science Ventures Funds II, Global Life Science Holding VIII and Alta California Partners |
| ||||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $16.3M |
||||
Company (Symbol)# | Partner (Country) | Amt. (M) | Triggering Event | Details (Date) |
Antigenics | Elan Corp. | ND | Milestone payment | Antigenics received a milestone payment for its the advancement of the vaccine, AN-1792, to a Phase IIa trial (12/19) |
| ||||
Atrix Lab- | Sanofi- | $3 | Milestone payment | Atrix earned a $3M milestone payment for the filing of the NDA for Leuprogel Three-Month Depot for the treatment of advanced prostate cancer (12/10) |
| ||||
Avanir | GlaxoSmith- | $5 | Milestone payment | Avanir earned the milestone payment for Abreva, a cold sore product (12/10) |
| ||||
Diversa Corp. | Zymetrics | $1.3 | Milestone payment | Diversa earned the milestone payment for its discovery and optimization of novel enzymes with potential application in feed and food processing (12/31) |
| ||||
Ligand | Elan Corp. | $1 | Milestone payment | Ligand received $1M for submitting a regulatory application to market Onzar in Europe to treat cutaneous T-cell lymphoma patients (12/19) |
| ||||
NPS Pharm- | Amgen Inc. | $6 | Milestone payments | NPS received $3M from each company for beginning a Phase III trial of AMG 073 to treat secondary hyperparathyroidism (12/21) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange |
||||
** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed; NDA = New drug application |
||||
AMEX = American Stock Exchange |